Alternatives to tobramycin
FDA shortage status is active for tobramycin; 3 same-class SPL records are listed below for registry comparison only.
Brand: Tobi, Nebcin
tobramycin class peers while FDA lists an active shortage
tobramycin (Tobi, Nebcin) is on an FDA shortage listing while 3 other Aminoglycoside Antibiotic SPL records remain in this registry peer set (class inventory 4). Labeled indication field for tobramycin: Tobramycin treats serious infections caused by bacteria.
Top FAERS reaction fields for tobramycin total 12,063 reports across 10 reactions, set beside amikacin, gentamicin, plazomicin. Counts are exposure-weighted submissions, not per-patient risk.
About tobramycin
Tobramycin is an antibiotic medicine. It fights serious bacterial infections in your body.
Used for: Tobramycin treats serious infections caused by bacteria. This includes infections in the blood, lungs, brain (meningitis), belly, skin, bones, and urinary tract. It is used when other antibiotics might not work or are too harmful.
3 Aminoglycoside Antibiotic peers (wide set)
amikacin
RxAmikin
Amikacin treats serious infections caused by bacteria. This includes infections in the blood, lungs, bones, joints, brain, skin, and abdomen. It can also treat burns, post-surgery infections, and complicated urinary tract infections.
gentamicin
RxGaramycin
Gentamicin treats serious infections caused by certain bacteria. This includes infections in the blood, brain (meningitis), urinary tract, lungs, stomach area, skin, bone, and soft tissues. It can also treat bacterial infections in newborns.
plazomicin
RxZemdri
Zemdri treats complicated urinary tract infections (cUTIs) in adults, including kidney infections (pyelonephritis). It is for infections caused by certain bacteria like Escherichia coli and Klebsiella pneumoniae. Because there is not much information on how safe and effective Zemdri is, use it only when other treatments are not an option.
tobramycin vs amikacin & gentamicin · FAERS reaction fields
FAERS top-reaction field "Infective Pulmonary Exacerbation Of Cystic Fibrosis" shows the widest count spread between tobramycin and amikacin, gentamicin, plazomicin in this extract (1,559-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | tobramycin | amikacin | gentamicin | plazomicin |
|---|---|---|---|---|
| Death | 1,667 | 1,103 | - | - |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis | 1,559 | - | - | - |
| Pneumonia | 1,453 | 649 | 333 | - |
| Dyspnoea | 1,373 | 1,556 | 337 | - |
| Cystic Fibrosis | 1,263 | - | - | - |
| Cough | 1,257 | 1,620 | - | - |
| Hospitalisation | 996 | 1,360 | - | - |
| Condition Aggravated | 942 | 566 | 404 | - |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
tobramycin shortage vs Aminoglycoside Antibiotic peer index
Shortage status
FDA shortage listing is active for tobramycin (status: To Be Discontinued). Peer rows remain a registry index, not a switch guide.
Frequently Asked Questions
Does FDA list a shortage for tobramycin while peers remain indexed? ▼
Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for tobramycin: see also the generic vs brand label guide when reading Tobi SPL strings.
Read our methodology - how this data is sourced, computed, and verified.